Tag:
pSivida
Latest Headlines
Latest Headlines
pSivida gets U.K. nod for behind-the-eye treatment
More good news for pSivida: The company's behind-the-eye macular edema treatment, Iluvien, picked up another approval.
pSivida stock rallies after Durasert partnerships
New applications for Durasert, pSivida's back-of-the-eye drug delivery tech, have helped the company nearly double its share price since January.
All eyes on pSivida for back-of-the-eye drug delivery
pSivida is getting more and more attention these days as a drug-delivery company to watch, especially as it develops products for a potentially huge market--easy delivery of medicine for glaucoma and
Pfizer, pSivida deal is about big market in patient compliance
Many ophthalmologists can tell you that patient compliance is one of the biggest hindrances to proper treatment. That's because there is some squeamishness about repeatedly squeezing a liquid into
pSivida forges $169M Pfizer pact for eye drug delivery program
Watertown, MA-based pSivida is pocketing a $2.3 million payment from Pfizer as is preps for a Phase I/II study a bioerodible eye implant designed to provide sustained release of latanoprost, a well
pSivida raises $11M in RDO
Following the FDA's decision in November to require more data analysis of it's eye disease drug Iluvien, pSivida announced that it's raising almost $11 million through a registered direct offering.
pSivida shares rocket up on late-stage eye drug data
Shares of pSivida rocketed up in overnight trading after investors got wind of the late-stage success of a new ophthalmic drug the biotech is co-developing with Alimera. The company reported that
